Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-021-00955-y, published online 10 June 2021.
In the version of this article initially published, WVE-120102 and WVE-120101 were described in the main text and WVE-003 in Table 1 as 2′-deoxy and 2′-O-methoxyethyl phosphorothioate triester ASOs. WVE-120102 and WVE-120101 are allele-selective stereodefined 2′-deoxy and 2′-O-methyl phosphorothioate and phosphorodiester chimeric ASOs. WVE-003 is an alelle-selective, stereopure ASO (structure not publicly available) that promotes RNase-H-mediated degradation of a mutant mRNA HTT species containing an undisclosed SNP. Also, WVE-120102 and WVE-120101 were described as targeting SNP1 (rs362307) and SNP2 (rs362331), respectively; the two SNPs here were transposed. Finally, they were described as being given in phase 1 testing; the trial was phase 1/2. The errors have been corrected in the PDF and HTML versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sheridan, C. Publisher Correction: Questions swirl around failures of disease-modifying Huntington’s drugs. Nat Biotechnol 39, 1017 (2021). https://doi.org/10.1038/s41587-021-01017-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01017-z